This drug is a type 5 Phosphodiesterase (PDE5) inhibitor. Oral administration of this drug can effectively improve the quality and duration of erection, and improve the success rate of sexual life of male patients with Erectile dysfunction. The initiation and maintenance of penile erection is related to the relaxation of smooth muscle cells in Cavernous tissue, and Cyclic guanosine monophosphate (cGMP) is the mediator that causes the relaxation of smooth muscle cells in Cavernous tissue. This drug can prevent the decomposition of cGMP by inhibiting type 5 Phosphodiesterase, so as to make cGMP accumulate, Cavernous tissue smooth muscle relax, and penis erect. Compared with Phosphodiesterase isoenzymes 1, 2, 3, 4 and 6, this drug has high selectivity for type 5 Phosphodiesterase. Some data show that its selectivity and inhibition on type 5 Phosphodiesterase are superior to other type 5 Phosphodiesterase inhibitor. It is speculated that this selectivity may reduce the cardiovascular and visual adverse reactions of this drug compared with other type 5 Phosphodiesterase inhibitor.






